LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kuhlmann, Jan D ^a   Schwarzenbach, Heidi ^b   Wimberger, Pauline ^a   Poetsch, Micaela ^a   Kimmig, Rainer ^a   Kasimir Bauer, Sabine ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Circulating DNA; Disseminated tumor cells; DNA fractionation; Loss of heterozygosity; Tumor suppressor genes

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING DNA; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW METASTASIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 6Q; DISEASE FREE SURVIVAL; FEMALE; FRACTIONATION; GENE LOCUS; GENE LOSS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 6; DNA, NEOPLASM; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864331647     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-325     Document Type: Article

References (42)

1. Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, Chen VW. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 2003, 97(10 Suppl):2676-2685.
2. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005, 16(Suppl 8):viii7-viii12.
3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115(6):1234-1244. 10.1002/cncr.24149, 19189349.
4. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009, 36(2):112-125. 10.1053/j.seminoncol.2008.12.003, 19332246.
5. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S. Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Genes Chromosomes Cancer 2011, 50(8):598-605. Epub 2011 May 11, 10.1002/gcc.20882, 21563231.
6. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775(1):181-232.
7. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11(6):426-437. 10.1038/nrc3066, 21562580.
8. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer 2011, 128(11):2572-2580. Epub 2010 Oct 26, 10.1002/ijc.25602, 20715113.
9. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987, 23(6):707-712. 10.1016/0277-5379(87)90266-5, 3653190.
10. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46(5):318-322. 10.1159/000226740, 2779946.
11. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, Janne PA. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15(8):2630-2636. 10.1158/1078-0432.CCR-08-2592, 2727796, 19351754.
12. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996, 2(9):1033-1035. 10.1038/nm0996-1033, 8782463.
13. Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000, 60(3):707-711.
14. Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, Blanchard RA, Rosenberg CL. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer 2003, 106(6):923-929. 10.1002/ijc.11333, 12918071.
15. Muller I, Beeger C, Alix-Panabieres C, Rebillard X, Pantel K, Schwarzenbach H. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008, 54(4):688-696. 10.1373/clinchem.2007.099333, 18281424.
16. Hung T, Mak K, Fong K. A specificity enhancer for polymerase chain reaction. Nucleic Acids Res 1990, 18(16):4953. 10.1093/nar/18.16.4953, 332015, 2395670.
17. Chevet E, Lemaitre G, Katinka MD. Low concentrations of tetramethylammonium chloride increase yield and specificity of PCR. Nucleic Acids Res 1995, 23(16):3343-3344. 10.1093/nar/23.16.3343, 307197, 7667112.
18. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006, 107(5):885-892. 10.1002/cncr.22076, 16874814.
19. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1(5):377-388. 10.1080/0032472031000141283, 20426539.
20. Wang M, Block TM, Steel L, Brenner DE, Su YH. Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004, 50(1):211-213. 10.1373/clinchem.2003.026914, 14709652.
21. Nakamura T, Sakai T, Nariya S. Cell death in colorectal polyps as evaluated by in situ 3'-tailing reaction and its relationship to BCL-2 expression. Pathol Int 1995, 45(10):721-728. 10.1111/j.1440-1827.1995.tb03388.x, 8563932.
22. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Torok L, Ellinger A, Mullauer L. Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett 1995, 82-83:143-148.
23. Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I. Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. Mod Pathol 1999, 12(6):604-611.
24. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18(1):65-73. 10.1023/A:1006260319913, 10505546.
25. Chun FK, Muller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, Graefen M, Pantel K, Huland H, Schwarzenbach H. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006, 98(3):544-548. 10.1111/j.1464-410X.2006.06352.x, 16925751.
26. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102(45):16368-16373. 10.1073/pnas.0507904102, 1283450, 16258065.
27. Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005, 92(12):2181-2184. 10.1038/sj.bjc.6602635, 2361808, 15928666.
28. Rawnaq T, Schwarzenbach H, Schurr PG, Freise K, Brandl S, Izbicki JR, Kaifi JT. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res 2011, 169(1):31-35. 10.1016/j.jss.2009.12.032, 20417938.
29. Schwarzenbach H, Muller V, Beeger C, Gottberg M, Stahmann N, Pantel K. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res 2007, 9(5):R66. 10.1186/bcr1772, 2242661, 17915011.
30. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P, Bonilla F. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002, 9(1):71-76. 10.1245/aso.2002.9.1.71, 11829433.
31. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, Stroun M, Provencio M, Espana P, Anker P, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000, 11(9):1097-1104. 10.1023/A:1008305412635, 11061602.
32. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011, 10(2):325-335. 10.1158/1535-7163.MCT-10-0788, 3037846, 21216927.
33. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010, 16(17):4325-4330. 10.1158/1078-0432.CCR-09-2990, 20622047.
34. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68(2):425-433. 10.1158/0008-5472.CAN-07-2488, 18199536.
35. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64(9):3014-3021. 10.1158/0008-5472.CAN-2401-2, 15126336.
36. Makhija S, Sit A, Edwards R, Aufman K, Weiss H, Kanbour-Shakir A, Gooding W, D'Angelo G, Ferrell R, Raja S, et al. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 2003, 90(1):3-9. 10.1016/S0090-8258(03)00177-X, 12821334.
37. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998, 47(3):295-302. 10.1023/A:1005915420341, 9516083.
38. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998, 47(3):269-281. 10.1023/A:1005959218524, 9516081.
39. Wood TL, Richert MM, Stull MA, Allar MA. The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 2000, 5(1):31-42. 10.1023/A:1009511131541, 10791766.
40. De Souza AT, Yamada T, Mills JJ, Jirtle RL. Imprinted genes in liver carcinogenesis. FASEB J 1997, 11(1):60-67.
41. Rey JM, Theillet C, Brouillet JP, Rochefort H. Stable amino-acid sequence of the mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines. Int J Cancer 2000, 85(4):466-473. 10.1002/(SICI)1097-0215(20000215)85:4<466::AID-IJC4>3.0.CO;2-2, 10699916.
42. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4(2):87-94.